Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426906 | 0.80 | CYP3A4 (0.43) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL17937995 | 0.79 | POLB (0.46) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL4050 | 0.77 | POLB (0.44) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2646513 | 0.76 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL8800000 | 0.76 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL262483 | 0.76 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10400040 | 0.76 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL11801523 | 0.76 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL13797901 | 0.76 | CYP3A4 (0.47) | POLBCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL3904945 | 0.75 | POLB (0.50) | POLBCYP3A4CYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | claimed |
| US-20100152439-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-17 | — | — | US | claimed |
| EP-2057142-A2 | METHOD FOR THE PREPARATION OF N-PIPERIDINYL-BENZODIAZEPINES HAVING CGRP-ANTAGONISTIC ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2009-05-13 | — | — | EP | claimed |
| WO-2008022962-A2 | METHOD FOR PRODUCING N-PIPERIDINYL-BENZODIAZEPINES HAVING CGRP-ANTAGONISTIC PROPERTIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | claimed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-20170271091-A1 | NON-AQUEOUS ELECTROLYTE, POWER STORAGE DEVICE USING SAME, AND LITHIUM SALT USED FOR SAME | UBE INDUSTRIES, LTD. (JP) | 2017-09-21 | — | — | US | disclosed |
| EP-3145019-A1 | NON-AQUEOUS ELECTROLYTE, POWER STORAGE DEVICE USING SAME, AND LITHIUM SALT USED FOR SAME | UBE Industries, Ltd. (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-7696346-B2 | 2-oxoethyl(1R)-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-[[3,5-dimethyl-4-(phenylmethoxy)phenyl]methyl]-2-[4-(4-morpholinyl)-1-piperidinyl]-1-piperidinecarboxylate; coupling alpha -hydroxy-3,5-dimethyl-4-(phenylmethoxy)-phenylpropionic acid-monosodium salt with 1,3-benzodiazepin compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696346-B2 | 2-oxoethyl(1R)-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-[[3,5-dimethyl-4-(phenylmethoxy)phenyl]methyl]-2-[4-(4-morpholinyl)-1-piperidinyl]-1-piperidinecarboxylate; coupling alpha -hydroxy-3,5-dimethyl-4-(phenylmethoxy)-phenylpropionic acid-monosodium salt with 1,3-benzodiazepin compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| EP-2057142-A2 | METHOD FOR THE PREPARATION OF N-PIPERIDINYL-BENZODIAZEPINES HAVING CGRP-ANTAGONISTIC ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008022962-A2 | METHOD FOR PRODUCING N-PIPERIDINYL-BENZODIAZEPINES HAVING CGRP-ANTAGONISTIC PROPERTIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008022962-A2 | METHOD FOR PRODUCING N-PIPERIDINYL-BENZODIAZEPINES HAVING CGRP-ANTAGONISTIC PROPERTIES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045705-A1 | Production Method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045705-A1 | Production Method | CYP2F1, CYP7A1, CYP1A1 | POLB 3971/4885CYP3A4 28/4885CYP2C9 18/4885 |
| US-20170271091-A1 | NON-AQUEOUS ELECTROLYTE, POWER STORAGE DEVICE USING SAME, AND LITHIUM SALT USED FOR SAME | HADH, GCDH, DHODH | POLB 576/4885CYP3A4 4215/4885CYP2C9 3250/4885 |
| US-20100152439-A1 | PRODUCTION METHOD | CYP2F1, CYP7A1, CYP1A1 | POLB 3971/4885CYP3A4 28/4885CYP2C9 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.